Table of Contents

• 1.1 List of Tables 4
• 1.2 List of Figures 6

2 Introduction 7

• 2.1 Individual and Specified Hormones Overview 7

3 Products under Development 8

• 3.1 Individual and Specified Hormones - Pipeline Products by Stage of Development 8
• 3.2 Individual and Specified Hormones - Pipeline Products by Segment 9
• 3.3 Individual and Specified Hormones - Pipeline Products by Territory 10
• 3.4 Individual and Specified Hormones - Pipeline Products by Regulatory Path 11
• 3.5 Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 12

4 Individual and Specified Hormones - Pipeline Products under Development by Companies 13

• 4.1 Individual and Specified Hormones Companies - Pipeline Products by Stage of Development 13
• 4.2 Individual and Specified Hormones - Pipeline Products by Stage of Development 14

5 Individual and Specified Hormones Companies and Product Overview 16

• 5.1 Alere Inc Company Overview 16
  • 5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 16
• 5.2 AMS Diagnostics LLC Company Overview 17
  • 5.2.1 AMS Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 17
• 5.3 Beckman Coulter Inc Company Overview 19
  • 5.3.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 19
• 5.4 Carolina Liquid Chemistries Corp Company Overview 20
  • 5.4.1 Carolina Liquid Chemistries Corp Pipeline Products & Ongoing Clinical Trials Overview 20
• 5.5 Ceres Nanosciences Inc Company Overview 22
  • 5.5.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 22
• 5.6 Columbia University Company Overview 23
  • 5.6.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 23
• 5.7 DIANA Biotechnologies Company Overview 24
  • 5.7.1 DIANA Biotechnologies Pipeline Products & Ongoing Clinical Trials Overview 24
• 5.8 DiaSorin SpA Company Overview 25
  • 5.8.1 DiaSorin SpA Pipeline Products & Ongoing Clinical Trials Overview 25
• 5.9 Immunodiagnostic Systems Holdings plc Company Overview 28
  • 5.9.1 Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 28
• 5.10 Novartis AG Company Overview 30
  • 5.10.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 30
• 5.11 OJ-Bio Ltd (Inactive) Company Overview 31
  • 5.11.1 OJ-Bio Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31
• 5.12 Roche Diagnostics International Ltd Company Overview 32
  • 5.12.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 32
• 5.13 Sendera Discovery Company Overview 37
  • 5.13.1 Sendera Discovery Pipeline Products & Ongoing Clinical Trials Overview 37
• 5.14 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 38
  • 5.14.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
• 5.15 Siemens Healthcare Diagnostics Inc Company Overview 44
  • 5.15.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
• 5.16 Siemens Healthineers AG Company Overview 51
  • 5.16.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 51
• 5.17 Tosoh Bioscience Inc Company Overview 52
  • 5.17.1 Tosoh Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 52

6 Individual and Specified Hormones- Recent Developments 53

• 6.1 Nov 04, 2019: Luminex reports third quarter 2019 results and submission of VERIGENE II Gastrointestinal Flex Assay to the FDA 53
• 6.2 Oct 16, 2019: Abbott reports third-quarter 2019 results 53
• 6.3 Oct 01, 2019: Fortress Diagnostics announces £8m investment in new headquarters 56
• 6.4 Sep 12, 2019: Repositioning of Biocrates: Management change and new round of financing 57
• 6.5 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 57
• 6.6 Jul 31, 2019: Luminex reports second quarter 2019 financial results and increase in quarterly dividend 58
• 6.7 Jul 29, 2019: Siemens Healthineers continues to drive growth forward 59
• 6.8 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers 60
• 6.9 Jul 17, 2019: Abbott reports second-quarter 2019 results 61
• 6.10 Jun 19, 2019: Immunodiagnostic Systems Holdings: Final results for year ended 31 March 2019 63

7 Appendix 85

• 7.1 Methodology 85
• 7.2 About GlobalData 88
• 7.3 Contact Us 88

Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019" provides an overview of Individual and Specified Hormones currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Individual and Specified Hormones pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Individual and Specified Hormones under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Individual and Specified Hormones and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Individual and Specified Hormones under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date